NFKB1 and pulmonary arterial hypertension: Due to the dynamic growth of knowledge on PAH, further research is also necessary in this field to evaluate TLR6 as a potential therapeutic target in PAH, which could be achieved by antagonizing signals in the TLR2/TLR6 heterodimer and NF-κB axis (Table 3) [15,42].